Arca
Skip to content

Ulcer

Drug research and approvals for ulcer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 557 studies of ulcer are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 557
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 557 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

4 approved, 7 in phase 3, 4 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Famotidine, Collagenase clostridium histolyticum, Ranitidine, Dimethicone

Macitentan
Phase 3 Endothelin receptor, ET-A/ET-B antagonist
Esomeprazole
Phase 3 Potassium-transporting ATPase inhibitor
Bosentan
Phase 3 Endothelin receptor, ET-A/ET-B antagonist
Cimetidine
Phase 3 Histamine H2 receptor antagonist
Pantoprazole
Phase 3 Potassium-transporting ATPase inhibitor
Becaplermin
Phase 3 Platelet-derived growth factor receptor agonist
Oxygen
Phase 3 Essential for cellular homeostasis
Isoniazid
Phase 2 Enoyl-[acyl-carrier-protein] reductase inhibitor
Onabotulinumtoxina
Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Riociguat
Phase 2 Soluble guanylate cyclase positive allosteric modulator
Omeprazole
Phase 2 Potassium-transporting ATPase inhibitor
Aspirin
Phase 1 Cyclooxygenase inhibitor

How Its Trials Ended

2,313 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 625 whose ending is known, 37% met their primary endpoint, 5% missed it and 57% stopped early.

  • Completed, result not reported91339%
  • Ongoing45720%
  • Status unknown31814%
  • Met its primary endpoint23210%
  • Stopped: other or unclear1607%
  • Stopped: enrollment or feasibility954%
  • Stopped: sponsor or business decision593%
  • Missed its primary endpoint341%
  • Stopped: lack of efficacy321%
  • Stopped: funding90%
  • Stopped: safety40%

FDA Orphan Designations

Approved first, then open designations, newest first
Jan 13, 2021TelacebecTreatment of Buruli ulcerThe Global Alliance for TB Drug Development, Inc.Designated
Aug 1, 1991Cyclosporine 2% ophthalmic ointmentFor use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcerAllergan, Inc.Designated

Medicines Authorised in the EU

Newest first
Jul 6, 2017OxervateCenegermin · orphanDompe' Farmaceutici S.p.A.EMA ↗
Aug 14, 1997Helicobacter Test INFAI13C-ureaINFAI, Institut für biomedizinische Analytik NMR-Imaging GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.